Show simple item record

dc.contributor.authorSande, Marianne A B van der
dc.contributor.authorRuijs, Wilhelmina L M
dc.contributor.authorMeijer, Adam
dc.contributor.authorCools, Herman J M
dc.contributor.authorPlas, Simone M van der
dc.date.accessioned2006-12-21T09:18:04Z
dc.date.available2006-12-21T09:18:04Z
dc.date.issued2006-11-10
dc.identifier.citationVaccine 2006, 24(44-46):6664-9en
dc.identifier.issn0264-410X
dc.identifier.pmid16797806
dc.identifier.doi10.1016/j.vaccine.2006.05.049
dc.identifier.urihttp://hdl.handle.net/10029/6691
dc.description.abstractTo assess the implementation of guidelines for using neuraminidase inhibitors in the control of influenza outbreaks in Dutch nursing homes, data were collected on prophylactic and therapeutic use of anti-viral medication, indications for use and criteria for prescribing, based on experiences during the influenza season 2004-2005 in a retrospective cross-sectional survey among Dutch nursing homes after the 2004-2005 season. Ninety/194 (49%) participating nursing homes reported an outbreak of influenza-like illness; in 57/194 (29%) influenza was laboratory confirmed. In 37/57 homes (65%) oseltamivir had been used as prophylaxis. Prophylactic use was extended to all residents and staff in 6/37 (16%) of homes, but limited in the others. In 9/37 (24%) no staff were issued prophylaxis. Among clinicians with laboratory confirmed influenza, 41/46 (89%) had used oseltamivir therapeutically. Main reasons for not prescribing oseltamivir for prophylaxis and/or therapy were lack of scientific evidence, high costs, and absent or delayed laboratory confirmation. Logistical bottlenecks in diagnosis, cost-effectiveness concerns, and lack of an evidence-base hamper full integration in policy and should be addressed.
dc.format.extent124439 bytes
dc.format.mimetypeapplication/pdf
dc.language.isoenen
dc.titleUse of oseltamivir in Dutch nursing homes during the 2004-2005 influenza season.en
dc.typeArticleen
dc.format.digYES
refterms.dateFOA2018-12-18T14:38:20Z
html.description.abstractTo assess the implementation of guidelines for using neuraminidase inhibitors in the control of influenza outbreaks in Dutch nursing homes, data were collected on prophylactic and therapeutic use of anti-viral medication, indications for use and criteria for prescribing, based on experiences during the influenza season 2004-2005 in a retrospective cross-sectional survey among Dutch nursing homes after the 2004-2005 season. Ninety/194 (49%) participating nursing homes reported an outbreak of influenza-like illness; in 57/194 (29%) influenza was laboratory confirmed. In 37/57 homes (65%) oseltamivir had been used as prophylaxis. Prophylactic use was extended to all residents and staff in 6/37 (16%) of homes, but limited in the others. In 9/37 (24%) no staff were issued prophylaxis. Among clinicians with laboratory confirmed influenza, 41/46 (89%) had used oseltamivir therapeutically. Main reasons for not prescribing oseltamivir for prophylaxis and/or therapy were lack of scientific evidence, high costs, and absent or delayed laboratory confirmation. Logistical bottlenecks in diagnosis, cost-effectiveness concerns, and lack of an evidence-base hamper full integration in policy and should be addressed.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
sande.pdf
Size:
121.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record